CD26 as a potential therapeutic target for lung adenocarcinoma
The correlation of CD26 expression in lung adenocarcinomas and better patient survival, the antiproliferative effect on tumor cells by CD26 inhibition, and an altered EMT status give rise to the hypothesis that CD26 inhibitors impact the biology and clinical course of lung adenocarcinomas.
Authors
- Alex Soltermann (ORCID: https://orcid.org/0000-0001-9509-6938)
- Florian Janker
- Alessandra Curioni‐Fontecedro (ORCID: https://orcid.org/0000-0002-5778-5270)
- Michaela B. Kirschner (ORCID: https://orcid.org/0000-0001-7444-9829)
- Birte Ohm (ORCID: https://orcid.org/0000-0001-8591-0473)
- Martina Haberecker (ORCID: https://orcid.org/0000-0001-5704-7721)
- Wolfgang Jungraithmayr (ORCID: https://orcid.org/0000-0002-1442-4862)
- Ignacio Gil‐Bazo (ORCID: https://orcid.org/0000-0002-2626-5109)
- Walter Weder (ORCID: https://orcid.org/0009-0008-3641-7568)
- Isabelle Opitz (ORCID: https://orcid.org/0000-0001-5900-9040)
- Jae–Hwi Jang
Institutions
- University of Fribourg (CH)
- University Medical Center Freiburg (DE)
- University Hospital of Zurich (CH)
- Fundación Instituto Valenciano de Oncología (ES)
- Fribourg Development Agency (CH)
- Clinica Universidad de Navarra (ES)
- Centro de Investigación Biomédica en Red de Cáncer (ES)
- University of Rostock (DE)
Publication Details
- Journal
- Frontiers in Oncology
- Published
- 2025-12-04
- DOI
- https://doi.org/10.3389/fonc.2025.1552587
- Primary Topic
- Peptidase Inhibition and Analysis
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Kurt und Senta Herrmann Stiftung
- Deutschen Konsortium für Translationale Krebsforschung